Details for New Drug Application (NDA): 211026
The generic ingredient in MACITENTAN is macitentan. There is one drug master file entry for this compound. Fifteen suppliers are listed for this compound. Additional details are available on the macitentan profile page.
Summary for 211026
| Tradename: | MACITENTAN |
| Applicant: | Lepu Pharm |
| Ingredient: | macitentan |
| Patents: | 0 |
Pharmacology for NDA: 211026
| Mechanism of Action | Endothelin Receptor Antagonists |
Suppliers and Packaging for NDA: 211026
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| MACITENTAN | macitentan | TABLET;ORAL | 211026 | ANDA | Novugen Pharma (USA) LLC | 82293-041 | 82293-041-10 | 1 BLISTER PACK in 1 CARTON (82293-041-10) / 15 TABLET, FILM COATED in 1 BLISTER PACK |
| MACITENTAN | macitentan | TABLET;ORAL | 211026 | ANDA | Novugen Pharma (USA) LLC | 82293-041 | 82293-041-20 | 30 TABLET, FILM COATED in 1 BOTTLE (82293-041-20) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 10MG | ||||
| Approval Date: | Dec 3, 2025 | TE: | AB | RLD: | No | ||||
| Regulatory Exclusivity Expiration: | Dec 3, 2026 | ||||||||
| Regulatory Exclusivity Use: | PATENT CHALLENGE | ||||||||
Complete Access Available with Subscription
